ATE478872T1 - Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung - Google Patents
Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendungInfo
- Publication number
- ATE478872T1 ATE478872T1 AT02007163T AT02007163T ATE478872T1 AT E478872 T1 ATE478872 T1 AT E478872T1 AT 02007163 T AT02007163 T AT 02007163T AT 02007163 T AT02007163 T AT 02007163T AT E478872 T1 ATE478872 T1 AT E478872T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- group
- cycloalkyl
- optionally substituted
- alkenyl
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000006193 alkinyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- -1 cycloheteroalkyl Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02007163A EP1348707B1 (de) | 2002-03-28 | 2002-03-28 | Pyrazolo[4,3-d]pyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE478872T1 true ATE478872T1 (de) | 2010-09-15 |
Family
ID=27798825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02007163T ATE478872T1 (de) | 2002-03-28 | 2002-03-28 | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7745450B2 (de) |
| EP (1) | EP1348707B1 (de) |
| JP (1) | JP2005527565A (de) |
| AT (1) | ATE478872T1 (de) |
| AU (1) | AU2003226731B2 (de) |
| CA (1) | CA2480409C (de) |
| DE (1) | DE60237425D1 (de) |
| DK (1) | DK1348707T3 (de) |
| WO (1) | WO2003082872A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| AU2004234158B2 (en) * | 2003-04-29 | 2010-01-28 | Pfizer Inc. | 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension |
| JP4681548B2 (ja) | 2003-07-22 | 2011-05-11 | アステックス・セラピューティクス・リミテッド | ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用 |
| GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
| GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| RU2006126791A (ru) * | 2003-12-23 | 2008-01-27 | Новартис АГ (CH) | Бициклические гетероциклические ингибиторы р-38 киназы |
| WO2005097799A1 (en) | 2004-04-07 | 2005-10-20 | Pfizer Limited | Pyrazolo`4,3-d! pyrimidines |
| RU2389731C2 (ru) * | 2004-06-02 | 2010-05-20 | Такеда Фармасьютикал Компани Лимитед | Конденсированное гетероциклическое соединение |
| ATE517901T1 (de) | 2004-09-06 | 2011-08-15 | Bayer Schering Pharma Ag | Pyrazolopyrimidine als hemmer der proteinkinase b (akt) |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| RU2425677C2 (ru) * | 2005-01-21 | 2011-08-10 | Астекс Терапьютикс Лимитед | Соединения, предназначенные для использования в фармацевтике |
| MX2007013215A (es) * | 2005-05-12 | 2007-12-12 | Pfizer | Formas cristalinas anhidras de la n-[1-(2-etoxietil)-5-(n-etil-n- metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo[4,3-d] pirimidina -3-carbonil] metanosulfonamida. |
| EP1915377A1 (de) | 2005-07-22 | 2008-04-30 | Sunesis Pharmaceuticals, Inc. | Als aurorakinaseinhibitoren geeignete pyrazolpyrimidine |
| NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
| FR2899107B1 (fr) | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| RU2009126576A (ru) | 2006-12-12 | 2011-01-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Конденсированное гетероциклическое соединение |
| US20090099195A1 (en) * | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| CN102272133A (zh) | 2008-11-06 | 2011-12-07 | 阿斯利康(瑞典)有限公司 | 淀粉样β的调节剂 |
| CZ2009358A3 (cs) * | 2009-06-03 | 2010-12-15 | C3 Bio Gmbh | 5,7-Disubstituované 3-isopropylpyrazolo[4,3-d]pyrimidiny pro použití jako lécivo a farmaceutické prípravky tyto látky obsahující |
| CZ302711B6 (cs) | 2009-06-03 | 2011-09-14 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující |
| TWI606049B (zh) * | 2011-04-21 | 2017-11-21 | 原真股份有限公司 | 新穎激酶抑制劑 |
| LT2734186T (lt) | 2011-07-22 | 2018-12-10 | Glaxosmithkline Llc | Kompozicija |
| AR090650A1 (es) * | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| WO2014031815A1 (en) | 2012-08-24 | 2014-02-27 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
| WO2014060112A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| RS56233B1 (sr) | 2012-11-20 | 2017-11-30 | Glaxosmithkline Llc | Nova jedinjenja |
| AU2013348216B2 (en) | 2012-11-20 | 2016-10-13 | Glaxosmithkline Llc | Novel compounds |
| WO2014081644A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| CN103405439B (zh) * | 2013-08-02 | 2014-12-31 | 上海市第十人民医院 | 嘧啶类化合物在制备真菌药物的应用 |
| CA2984949A1 (en) * | 2015-03-16 | 2016-09-22 | Monash University | Treatment of skin conditions |
| CZ307147B6 (cs) * | 2015-05-14 | 2018-02-07 | Ústav experimentální botaniky AV ČR, v. v. i. | 5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky |
| EP3528813B1 (de) | 2016-09-30 | 2025-04-16 | ABS Development 1, Inc. | P2x3- und/oder p2x2/3-verbindungen und verfahren |
| CZ308484B6 (cs) * | 2018-02-05 | 2020-09-16 | Univerzita PalackĂ©ho v Olomouci | 5-Alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidiny pro léčení lymfomů |
| EP3797776B1 (de) * | 2019-09-30 | 2025-07-23 | Universitätsmedizin Mainz | Cdk4/6-hemmer zur behandlung von psoriasis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3988338A (en) * | 1974-04-24 | 1976-10-26 | Wisconsin Alumni Research Foundation | 4-Substituted amino-2-substituted thio-pyrrolo-[2,3-d]pyrimidine derivatives |
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| US5276143A (en) | 1990-12-21 | 1994-01-04 | E. I. Du Pont De Nemours And Company | Dideoxyfructonucleosides and deoxyfructonucleotides |
| US5801015A (en) | 1995-06-05 | 1998-09-01 | Mitotix, Inc. | Nucleic acid encoding a Candida cell cycle regulatory protein, TYP1 polypeptide |
| US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
| ES2200039T3 (es) * | 1995-12-08 | 2004-03-01 | Pfizer Inc. | Derivados heterociclicos sustituidos como antagonistas de crf. |
| TR199900389T2 (xx) * | 1996-08-28 | 2000-06-21 | Pfizer Inc. | �kame edilmi� 6,5-hetero-bisiklik t�revleri. |
| US5723608A (en) * | 1996-12-31 | 1998-03-03 | Neurogen Corporation | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
| KR100441229B1 (ko) * | 1997-04-25 | 2004-07-22 | 화이자 인코포레이티드 | 타입 5 시클릭 구아노신 3',5'-모노포스페이트 포스포디에스테라제(ｃＧＭＰ ＰＤＥ5)를 억제하는 성기능 장애 치료용 피라졸로피리미디논 |
| US5985848A (en) * | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| HUP0102543A3 (en) * | 1998-04-20 | 2002-01-28 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them |
| JP2002528456A (ja) * | 1998-10-23 | 2002-09-03 | ファイザー・インク | 性的機能障害の処置のためのピラゾロピリミジノン系ｃＧＭＰ阻害薬 |
| AU1888800A (en) * | 1999-09-13 | 2001-04-17 | Cipla Limited | A novel process for the synthesis of sildenafil citrate |
| AU779761C (en) * | 1999-10-12 | 2005-09-22 | Lilly Icos Llc | Medicament for treatment of neuropathies |
| DE10060388A1 (de) * | 2000-12-05 | 2002-06-06 | Merck Patent Gmbh | Verwendung von Pyrazolo [4,3-d]pyrimidinen |
| HUP0303315A2 (hu) * | 2000-12-19 | 2004-01-28 | Merck Patent Gmbh. | Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények |
| GB0106661D0 (en) * | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
| PL370599A1 (en) * | 2001-11-02 | 2005-05-30 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
-
2002
- 2002-03-28 EP EP02007163A patent/EP1348707B1/de not_active Expired - Lifetime
- 2002-03-28 AT AT02007163T patent/ATE478872T1/de not_active IP Right Cessation
- 2002-03-28 DK DK02007163.5T patent/DK1348707T3/da active
- 2002-03-28 DE DE60237425T patent/DE60237425D1/de not_active Expired - Lifetime
-
2003
- 2003-03-27 AU AU2003226731A patent/AU2003226731B2/en not_active Ceased
- 2003-03-27 JP JP2003580337A patent/JP2005527565A/ja active Pending
- 2003-03-27 CA CA2480409A patent/CA2480409C/en not_active Expired - Fee Related
- 2003-03-27 WO PCT/EP2003/003207 patent/WO2003082872A1/en not_active Ceased
-
2004
- 2004-09-28 US US10/952,087 patent/US7745450B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2480409A1 (en) | 2003-10-09 |
| DK1348707T3 (da) | 2010-12-13 |
| JP2005527565A (ja) | 2005-09-15 |
| DE60237425D1 (de) | 2010-10-07 |
| WO2003082872A1 (en) | 2003-10-09 |
| US7745450B2 (en) | 2010-06-29 |
| CA2480409C (en) | 2010-06-22 |
| AU2003226731B2 (en) | 2008-05-22 |
| AU2003226731A1 (en) | 2003-10-13 |
| US20050080097A1 (en) | 2005-04-14 |
| EP1348707A1 (de) | 2003-10-01 |
| EP1348707B1 (de) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE478872T1 (de) | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung | |
| CA2184919A1 (en) | New Piperazine Derivatives and Methods for the Preparation Thereof and Compositions Containing the Same | |
| BG107120A (bg) | Нови бавнодействащи бетамиметици, метод за тяхното получаване и приложението им като лекарствени средства | |
| CA2337041A1 (en) | Aminomethylcarboxylic acid derivatives | |
| WO2003076458A3 (en) | Selective dipeptide inhibitors of kallikrein | |
| CA2368413A1 (en) | Derivatives of pyrimido[6,1-a]isoquinolin-4-one | |
| MXPA06001274A (es) | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. | |
| HUP0301671A2 (hu) | 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk | |
| ATE225348T1 (de) | Substituierte azaindolylidenderivate und verfahren zu ihrer herstellung | |
| WO2005092858A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist | |
| MY141504A (en) | Gamma secretase inhibitors | |
| TW368501B (en) | 7-(2-aminoethyl)-benzothiazolones | |
| TW235297B (de) | ||
| JP2005538111A5 (de) | ||
| CA2213080A1 (en) | 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists | |
| EP2289888A3 (de) | Epoxidcarboxylsäureamide, Azide und Aminoalkohole sowie Verfahren zur Herstellung von Alpha-Ketoamiden damit | |
| MY138051A (en) | Compounds and processes | |
| TW200420559A (en) | Amine compounds and method for producing the same | |
| AR023914A1 (es) | Caprolactamas sustituidas, un proceso para su preparacion, composiciones farmaceuticas que las contienen, y su uso para la preparacion de composicionesfarmaceuticas en el tratamiento de tumores | |
| EP0431520A3 (en) | Heterocyclic acyl aminodiol beta-amino acid derivatives | |
| DE50202381D1 (de) | Geschützte tyrosinderivate, verfahren zu deren herstellung und deren verwendung zur herstellung von o-(2- ?18 f]-fluorethyl)-l-tyrosin | |
| GB0113232D0 (en) | Chemical process | |
| MXPA01009768A (es) | Analogos de fenoxazina utiles como inhibidores de la agregacion amiloide y para el tratamiento de la enfermedad de alzheimer y las enfermedades relacionadas con la amiloidosis. | |
| TW200510300A (en) | Amino alcohol compounds | |
| EP1683782A3 (de) | Chiraler Kupfercomplex, Produktionsverfahren dafür und Anwendung davon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |